Equity Overview
Price & Market Data
Price: $1.45
Daily Change: -$0.05 / 3.45%
Daily Range: $1.43 - $1.51
Market Cap: $24,176,034
Daily Volume: 180,582
Performance Metrics
1 Week: 0.69%
1 Month: -33.79%
3 Months: 43.56%
6 Months: 25.00%
1 Year: -11.04%
YTD: -2.68%
Company Details
Employees: 5
Sector: Health technology
Industry: Biotechnology
Country:
Details
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.